Advert for Healthcare Professionals Only
I am a patient (Please go to our patient website)
- All Topics
- Allergy and Clinical Immunology
- Anesthesiology
- Angiology
- Cardiology
- Central Nervous System
- Clinical Laboratory
- Complementary and Alternative Medicine
- Critical Care/Intensive Care
- Dermatology
- Diabetes and Endocrinology
- Ear, Nose and Throat
- Emergency Medicine
- Eye Health and Disorders
- Family Medicine
- Gastroenterology
- Gerontology/Geriatrics
- Haematology
- Hepatology
- HIV/AIDS
- Immunology
- Infectious Diseases
- Internal Medicine
- Kidney and Urological Diseases
- Medical Genetics
- Men's Health, Andrology and Urology
- Musculoskeletal Disorders
- Neonatal/Perinatal Medicine
- Neurological Disorders
- Nutrition and Dietetics
- Oncology
- Orthopaedics
- Paediatrics
- Pain Management
- Palliative Medicine
- Plastic Surgery and Aesthetic Medicine
- Podiatry
- Preventive Medicine
- Psychiatry/Mental Health
- Radiology
- Respiratory
- Rheumatology
- Sexual Health
- Sleep Medicine
- Sports Medicine
- Surgery (General)
- Transplantation
- Tropical Medicine
- Vaccines
- Women's Health and Obs/Gyn
- ADHD
- Alzheimer's Disease
- Arthritis
- Atopic Dermatitis
- Cholesterol
- Chronic Myeloid Leukemia
- COPD
- Cystic Fibrosis
- Diabetes
- Gastrointestinal Stromal Tumours
- Hepatitis
- Hypertension
- Insomnia
- Lysosomal Storage Disorders
- Men's Health
- Multiple Sclerosis
- Niemann-Pick type C
- NSCLC
- Opioids and Pain
- Parkinson's Disease
- Post-Myocardial Infarction
- Prostate Cancer
- Renal Anaemia
- Renal Cell Carcinoma
- Soft Tissue Sarcoma
- Third Party Website - Asthma and COPD
- CAPOZIDE TABLETS
- SURMONTIL 10MG AND 25MG TABLETS
- NAPRATEC OP
- COBALIN-H INJECTION
- CARBEX
- CALCIUM RESONIUM 99.934% W/W POWDER FOR ORAL/RECTAL SUSPENSION
- HYPURIN BOVINE ISOPHANE
- HYPURIN BOVINE LENTE
- HYPURIN PORCINE 30/70 MIX CARTRIDGES
- HYPURIN BOVINE ISOPHANE VIALS
- DUKORAL ORAL CHOLERA VACCINE
- OXYNORM LIQUID 5 MG/5 ML ORAL SOLUTION
- DORZOLAMIDE/TIMOLOL EYE DROPS
- FENOFIBRATE 267MG CAPSULES
- TRACRIUM INJECTION
- EXOCIN
- FRAGMIN - TREATMENT OF VTE
- FLUDARABINE PHOSPHATE 50 MG POWDER FOR SOLUTION FOR INJECTION OR INFUSION
- GABITRIL FILM-COATED TABLETS (5 , 10, 15 MG)
- PROTOPIC 0.03% OINTMENT
- XISMOX 60 XL PROLONGED RELEASE TABLETS
- PALLADONE SR CAPSULES
- ZINERYT
- PURI-NETHOL 50 MG TABLETS
- DAKTACORT OINTMENT
- MYLERAN 2 MG FILM-COATED TABLETS
- NEOTIGASON 10MG CAPSULES
- LEUKERAN TABLETS 2 MG
- LANVIS TABLETS 40 MG
- PROVIGIL 100 MG TABLETS, PROVIGIL 200 MG TABLETS
- ADHD
- Alzheimers
- Anxiety Disorders
- Arthritis
- Asthma
- Avonex
- Breast Cancer
- Cervical Cancer
- Cholesterol
- Colorectal Cancer
- Copaxone
- Depression
- Diabetes
- Erectile Dysfunction
- Extavia
- Hypertension
- Insomnia
- Men's Health
- Meningitis
- Migraine
- Pain Management
- Parkinson's
- Pharma News
- Post-MI
- Pregnancy
- Prostate
- Rebif
- Renal anaemia
- Renal Cell Carcinoma
- Thrombosis
- Thromboembolism
- Tysabri
Advert for Healthcare Professionals Only
Gastroenterology Drug Data - A-Z (English)
Drug Class Description
H2 -antagonists (H2 -receptor antagonists / H 2 -blockers).Generic Name
Ranitidine hydrochlorideDrug Description
Zantac Tablets: 150mg white five- sided f-c tablets; 300mg white f-c tablets. Both marked with tablet name, strength and GLAXO. Zantac Syrup: sugar-free syrup. Zantac Injection: solution in ampoules. Zantac Effervescent: white effervescent tablets.Presentation
Zantac Tablets: Ranitidine (as hydrochloride) 150mg , 300mg . Zantac Syrup: Ranitidine (as hydrochloride) 150mg per 10mL, ethanol 7.5%. Zantac Injection: Ranitidine (as hydrochloride) 50mg per 2mL. Zantac Effervescent: Ranitidine (as hydrochloride) 150mg , 300mg .Indications
Treatment of duodenal, benign gastric and post-operative ulceration, including that due to NSAIDs. Prevention of NSAID induced duodenal ulcers. Duodenal ulcers associated with Helicobacter pylori . Oesophageal reflux, reduction of gastric acid, chronic episodic dyspepsia. Moderate to severe oesophagitis. Zollinger-Ellison syndrome. Prophylaxis of haemorrhage in stress ulcer or bleeding peptic ulcer. Prophylaxis of acid aspiration during general anaesthesia.Adult Dosage
Duodenal and gastric ulcer, 150 mg twice daily or 300 mg at bedtime for four weeks or 300 mg twice daily; maintenance, 150 mg at bedtime. DU with H. pylori , 300 mg at bedtime or 150 mg twice daily for four weeks plus amoxicillin 750 mg three times daily and metronidazole 500 mg three times daily for first 2 weeks. Prevention of NSAID induced duodenal ulcer, 150 mg twice daily. Reflux oesophagitis, 150 mg twice daily or 300 mg at bedtime for up to 12 weeks. If moderate to severe, 150 mg four times daily for up to 12 weeks. Long term treatment of healed oesophagitis, 150 mg twice daily. Zollinger-Ellison syndrome, 150 mg three times daily. Increase to 6 g daily if necessary. Chronic episodic dyspepsia, 150 mg twice daily for up to 6 weeks. Prophylaxis of haemorrhage, 150 mg twice daily substituted for inj. once oral feeding commences.Child Dosage
Under 2 years, not recommended; over 2 years, peptic ulceration only, 2 - 4 mg/kg twice daily; maximum 300 mg daily. Exclude malignant disease before treatment. Impaired renal function. Pregnancy. Lactation.Adverse Reactions
Headache, dizziness. Rarely hepatitis, thrombocytopenia, leucopenia, hypersensitivity, confusion, breast symptoms.Manufacturer
GlaxoSmithKline(GSK)Drug Availability
(POM)Advert for Healthcare Professionals Only
Related News
FDA approves Remicade for Pediatric Ulcerative Colitis Gastroenterology Page
The FDA has approved Remicade (infliximab), from Janssen Biotech, for the treatment of moderately to severely active Ulcerative Colitis (UC) in pediatric patients who have had an inadequate response to conventional therapy. The approval was supported by evidence from studies of Remicade in adults with Ulcerative Colitis plus additional data from a pivotal Phase III trial evaluating the efficacy and safety of Remicade in the treatment of pediatric patients. Results from the pediatric UC study presented in May 2011 showed that treatment with Remicade 5 mg/kg induced clinical response in 73 percent of patients at week 8 and demonstrated a safety profile consistent with previous clinical trials conducted in an adult population.
FDA approves anti-Helicobacter pylori antibody Gastroenterology Page
The FDA has given 510(K) approval to Ventana anti-Helicobacter pylori (SP48) Rabbit Monoclonal Primary Antibody (H. pylori), from Ventana Medical Systems. This antibody is the first H. pylori antibody to receive such clearance and when used in immunohistochemical staining, aids in the detection of Helicobacter pylori, a bacterium linked to Chronic Gastritis, Ulcers and Stomach Cancer. The antibody provides pathologists unprecedented views of the bacterium, allowing for a more accurate patient diagnosis and is also fully integrated with the Ventana BenchMark XT and BenchMark Ultra slide staining instruments.
Napo Pharma terminates agreement wit Salix Pharma for crofelemer for Chronic Diarrhoea in AIDS patients Gastroenterology Page
Napo Pharma has terminated its agreement with Salix Pharma for failure of Salix Pharma to proceed with an application to the FDA for crofelemer for chronic diarrhoea in people living with HIV/AIDS, despite a successful Phase III result. Napo has filed a lawsuit against Salix seeking $150 million for breach of contract.
